KalVista Pharmaceuticals Sees Surge in Shares on Phase 3 Sebetralstat Success
KalVista Pharmaceuticals shares skyrocketed over 35% in premarket trading today following the announcement of successful late-stage study results for...
hereditary angioedema
KalVista’s Sebetralstat Study Shows Promising Results for Hereditary Angioedema
In a major breakthrough, KalVista Pharmaceuticals announced that its late-stage study of sebetralstat, a therapy for hereditary angioedema, has...
Ionis Pharmaceuticals and Otsuka Collaborate to Bring Rare Disease Drug to Europe
Ionis Pharmaceuticals has entered into a license agreement with Otsuka Pharmaceutical to bring its donidalorsen treatment for hereditary angioedema...
Intellia Therapeutics Shares Rise 10% After EU Grants Orphan Drug Designation for NTLA-2002
Intellia Therapeutics' shares have surged 10% after the European Commission granted orphan drug designation to their therapy, NTLA-2002, for...
KalVista Pharma Hits Milestone in Sebetralstat Trial
KalVista Pharmaceuticals has reached a significant milestone in its clinical trial for sebetralstat, a potential oral therapy for hereditary...